14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
XHE vs MDEV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, SPDR S&P Health Care Equipment ETF (XHE) is the stronger overall head-to-head candidate over First Trust Indxx Medical Devices ETF (MDEV) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). XHE carries a Unified Composite Score of 46.8/100 (HOLD) at $93.61 (N/M Forward P/E, N/A operating margin), whereas MDEV carries 41.2/100 (SELL) at $22.56 (N/M Forward P/E, N/A operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XHE vs MDEV. Trailing 12-month operating profitability (XHE N/A vs MDEV N/A) and valuation multiples (XHE N/M vs MDEV N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ XHE vs MDEV Key Questions & Quantitative Answers
As of Nov 16, 2026, SPDR S&P Health Care Equipment ETF (XHE) is the stronger overall head-to-head candidate over First Trust Indxx Medical Devices ETF (MDEV) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). XHE carries a Unified Composite Score of 46.8/100 (HOLD) at $93.61 (N/M Forward P/E, N/A operating margin), whereas MDEV carries 41.2/100 (SELL) at $22.56 (N/M Forward P/E, N/A operating margin). Technically, XHE sits in a Neutral phase (RSI 50.3, UNCLASSIFIED options structure) and MDEV sits in a Markup phase (RSI 57.5, UNCLASSIFIED options structure).
XHE and MDEV split Growth & Scale metrics: XHE posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with MDEV at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, XHE generates N/A in USD-normalized revenue versus N/A for MDEV. In operating R&D and SG&A reinvestment, XHE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MDEV.
XHE and MDEV trade at balanced relative valuation multiples. XHE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MDEV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XHE (N/A ROE) versus MDEV (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, XHE carries 252.7% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 39% Vol realized risk). By comparison, MDEV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.55β · 25% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.